在多发性硬化症中保持运动和平衡:一项系统性审查,检查症状药物治疗的潜在影响
Alyssa A Jones1,2, Rudri Purohit1,3, Tanvi Bhatt1
1Department of Physical Therapy, University of Illinois at Chicago, Chicago, IL, USA.
CNS drugs
|February 15, 2025
概括
范普里丁在改善多发性硬化症 (MS) 患者的行动能力和步态方面表现有前途. 其他症状药物可能有助于性,但对移动性标志物的影响有限.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 康复科学 康复科学 康复科学
背景情况:
- 运动障碍 (MD) 影响超过90%的多发性硬化症 (MS) 患者在10年内.
- 症状性药物疗法用于管理正在进行的MS进展及其对移动性的影响.
研究的目的:
- 系统审查随机对照试验 (RCT) 的症状药物疗法,影响多发性硬化症 (MD) 标志物.
- 评估这些治疗对步态,平衡和功能移动性的疗效和影响.
主要方法:
- 从1990年到2024年使用PubMed,Scopus和谷歌学者进行RCT的系统审查.
- 纳入标准:确认MS诊断,MD结果,症状性药物治疗使用.
- 使用PEDRo尺度评估偏差风险;使用Rayyan软件选数据.
主要成果:
- 包括23个RCT:13个是针对fampridine,10个是针对cannabinoids,1个是针对baclofen.
- 普利丁显著改善了步行速度,耐力和功能性移动性;平衡效应没有确定性.
- 大麻素主要减少了性,对疼痛或MD结果的影响有限. 对所有疗法都注意到了不良反应.
结论:
- 芬普里丁可以增强MS患者的步态和功能移动性,这需要进一步的平衡研究.
- 大麻素和巴克洛芬可能会缓解性,但对MD标志物具有有限的次要影响.
- 整合康复与药物治疗可以优化MS的MD管理.
相关概念视频
01:24Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
01:28Drug Therapy
35
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
35
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K